Virus Or Component Thereof Patents (Class 424/204.1)
  • Patent number: 10279028
    Abstract: Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 7, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Renukaradhya J. Gourapura, Varun Dwivedi, Basavaraj S. Binjawadagi, Jordi Torrelles
  • Patent number: 10253294
    Abstract: The present invention relates to a method for producing dendritic cells with increased capability to activate T cells, to dendritic cells obtainable by such a method, and to a pharmaceutical composition comprising such dendritic cells.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: April 9, 2019
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Marion Heuer, Manfred Lutz, Andreas Beilhack
  • Patent number: 10206993
    Abstract: This invention provides a multivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a Lawsonia intracellularis antigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 19, 2019
    Assignee: Zoetis Services LLC
    Inventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 10174084
    Abstract: The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: January 8, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventor: Takanori Sato
  • Patent number: 10144975
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: December 4, 2018
    Assignees: INSTITUT PASTEUR, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, PATHOQUEST, ECOLE NATIONALE VETERINAIRE D'ALFORT
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Patent number: 10130698
    Abstract: The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 20, 2018
    Assignee: Intervet Inc.
    Inventors: Vicky Fachinger, Melanie Sno, Maarten Hendrik Witvliet
  • Patent number: 10105440
    Abstract: In one aspect, the present disclosure provides compounds of formulae I and II. In another aspect, a compound of formula I or II is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 23, 2018
    Assignee: Variation Biotechnologies Inc.
    Inventor: Maura Ellen Campbell
  • Patent number: 10100101
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: October 16, 2018
    Assignee: Ohio State Innovation Foundation
    Inventor: Daral John Jackwood
  • Patent number: 10071150
    Abstract: An immunity enhancing therapeutic vaccine includes a gene vector based on recombinant adenovirus and three elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18, 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis, and 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The vaccine is used for the treatment of human papilloma virus infections and related diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: September 11, 2018
    Assignee: MYGT Biopharmaceutical LLC
    Inventors: Tao Bian, Juan Li, Xiao Xiao
  • Patent number: 10064924
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Kowalewski, Claudia Berlin
  • Patent number: 10052375
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 21, 2018
    Assignee: Zoetics Services LLC
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Patent number: 10039820
    Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 7, 2018
    Assignee: Hawaii Biotech, Inc.
    Inventors: Beth-Ann Coller, Vidya Pai, Carolyn L. Weeks-Levy, Steven A. Ogata
  • Patent number: 10034929
    Abstract: The disclosure provides recombinant viral vectors and attenuated viruses and viral vaccines comprising a virus lacking a functional viral RNA suppressor of host RNAi.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: July 31, 2018
    Assignee: The Regents of the University of California
    Inventors: Shou-Wei Ding, Yang Li
  • Patent number: 10010602
    Abstract: A fusion protein comprising an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a translocation peptide, a fusion antigen, an endoplasmic reticulum retention sequence, and optionally a nuclear export signal is disclosed. The fusion antigen comprises a porcine reproductive and respiratory syndrome virus (PRRSV) ORF7 antigen, a PRRSV ORF1b antigen, a PRRSV ORF6 antigen, and a PRRSV ORF5 antigen. The fusion protein is useful for inducing antigen-specific cell-mediated and humoral responses.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 3, 2018
    Assignee: REBER GENETICS CO., LTD.
    Inventors: Yu-Hsin Chien, Meng-Ju Tsai, Pao-Yen Lai, Wei-I Chou, Hsiu-Kang Chang
  • Patent number: 9993545
    Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 12, 2018
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David B. Weiner, Jian Yan, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Patent number: 9987350
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human Enterovirus B, Human enterovirus C, Human Enterovirus D antigens and their use in vaccines for the prevention of an enterovirus infection.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: June 5, 2018
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Patent number: 9970067
    Abstract: This invention relates to primers and probes for detecting Ebola virus and one or more subtypes of Ebola virus as well as kits including the probes and primers and methods of using the probes and primers.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 15, 2018
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Scott Rose, Kristin Beltz
  • Patent number: 9969986
    Abstract: A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: May 15, 2018
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Patent number: 9956281
    Abstract: The present invention is directed at a composition comprising a live swine flu virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. Preferably, the formaldehyde donor agent is selected from a non-crosslinking chemical fixative that contains urea.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: May 1, 2018
    Assignee: STRECK, INC.
    Inventors: Wayne L. Ryan, James A Grunkemeyer
  • Patent number: 9944904
    Abstract: This invention relates to a method for rapid production of PCV2 such that an optimum yield of the virus can be obtained. This invention also relates to the vaccine useful against PCV2 which includes the PCV2 propagated using such a method.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: April 17, 2018
    Assignee: MERIAL INC.
    Inventors: Paulraj Lawrence, Frederic Dumas
  • Patent number: 9925255
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9925256
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9919041
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9872898
    Abstract: Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: January 23, 2018
    Assignee: Ohio State Innovation Founation
    Inventors: Renukaradhya J. Gourapura, Varun Dwivedi, Basavaraj S. Binjawadagi, Jordi Torrelles
  • Patent number: 9867835
    Abstract: A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: January 16, 2018
    Assignee: ENTERIN LABORATORIES, INC.
    Inventor: Michael Zasloff
  • Patent number: 9833407
    Abstract: The present invention provides a nasal vaccine for Streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of PspA, i.e. the vaccine antigen, and a nanogel in which hydrophobic cholesterol is added, as side chains, to pullulan having amino groups. Furthermore, the present invention provides a production method for the nasal vaccine formulation for primates.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: December 5, 2017
    Assignee: Intellectual Property Strategy Network, Inc.
    Inventors: Yoshikazu Yuki, Hiroshi Kiyono, Kazunari Akiyoshi, Shinichi Sawada
  • Patent number: 9814771
    Abstract: The role of a specific E2 region containing a putative fusion peptide (FP) sequence was evaluated. FPs critically contribute to the interaction between proteins and the membrane system of the host cell. Reverse genetics utilizing a full-length infectious clone of the highly virulent CSFV strain Brescia (BICv) was used to evaluate how amino acid substitutions within this region of E2 may affect replication of BICv in cell cultures and affect virus virulence in swine. Interestingly, mutated virus FPi.c was completely attenuated when inoculated intranasally at a dose of 105 TCID50 in swine. Importantly, animals infected with FPi.c virus were protected against the virulent challenge with Brescia virus at 3 and 28 days after vaccination. Protection was evidenced by absence of clinical signs related with CSF as well as the absence of viremia produced by the challenge virulent virus.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: November 14, 2017
    Assignees: The United States of America, as represented by The Secretary of Agriculture, The University of Connecticut, Universidad del Pais Vasco/Euskal Herriko Univertsitatea (UPV-EHU)
    Inventors: Manuel V. Borca, Douglas P. Gladue, Lauren G. Holinka-Patterson, Vivian O'Donnell, Jose Nieva
  • Patent number: 9803199
    Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: October 31, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
  • Patent number: 9795666
    Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: October 24, 2017
    Assignee: Academia Sinica
    Inventors: Pei-Wen Hsiao, Chia-Ying Wu, Yi-Chun Yeh
  • Patent number: 9796996
    Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: October 24, 2017
    Assignee: UNIVERSITEIT UTRECHT HOLDING B.V.
    Inventors: Petrus Josephus Marie Rottier, Hui-wen Chang, Herman F. Egberink
  • Patent number: 9764022
    Abstract: Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: September 19, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christopher B. Buck, Diana V. Pastrana
  • Patent number: 9758787
    Abstract: The present disclosure provides, inter alia, Thraustochytrium and relevant methods and reagents, including engineered regulatory sequences from and/or operative in Thraustochytrid or Thraustochytrium, selectable markers useful for engineering microorganisms such as Thraustochytrids, means for mutagenizing microorganisms, novel strains produced by mutagenesis, and methods and compositions related to production of particular compounds in microorganisms.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: September 12, 2017
    Assignee: DSM NUTRITIONAL PRODUCTS AG
    Inventors: ShuoCheng Zhang, Roberto E. Armenta
  • Patent number: 9751912
    Abstract: In one or a plurality of embodiments, there is provided a target molecule of amylospheroid, which is expressed in mature neurons and to which the amylospheroid binds to induce death of cells. Further, in one or a plurality of embodiments, there is provided a method and a substance for inhibiting death of mature neurons induced by the amylospheroid. In one aspect, the present disclosure relates to a use of Na+/K+-ATPase ?3 as a binding target molecule of amylospheroid. In another aspect, the present disclosure relates to a method for suppressing death of mature neurons induced by the amylospheroid, including inhibiting protein-protein interaction between the amylospheroid and the Na+/K+-ATPase ?3, and the like.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: September 5, 2017
    Assignee: TAO HEALTH LIFE PHARMA CO., LTD.
    Inventor: Minako Hoshi
  • Patent number: 9738691
    Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: August 22, 2017
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Shaowei Li, Minxi Wei, Xianglin Kong, Yingbin Wang, Jun Zhang, Ningshao Xia
  • Patent number: 9730921
    Abstract: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 15, 2017
    Assignee: Duke University
    Inventors: Soman N. Abraham, Ashley L. St. John
  • Patent number: 9701725
    Abstract: Novel nucleic acid vectors comprising sequences encoding (a) an antigen, (b) a signal peptide, and (c) a heat shock protein, are disclosed, as are methods for using such vectors to induce antigen-specific immune responses and to treat tumors.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: July 11, 2017
    Assignee: The Johns Hopkins University
    Inventors: Tzyy-Choou Wu, Chien-Fu Hung
  • Patent number: 9701723
    Abstract: Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: July 11, 2017
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Taia T. Wang, Gene S. Tan
  • Patent number: 9682136
    Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: June 20, 2017
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Chaouki Miled, Frédéric Tangy, Yves Jacob
  • Patent number: 9683021
    Abstract: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: June 20, 2017
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Delbert L. Harris, Matthew M. Erdman
  • Patent number: 9675550
    Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: June 13, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria A. Croyle, Jun Huk Choi, Stephen Schafer
  • Patent number: 9675571
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 13, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Steven P. Seitz, Amy C. Hart, Jay A. Markwalder
  • Patent number: 9669087
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 6, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9669088
    Abstract: H5N1 influenza viruses isolated from animals and humans since 2003 separate into distinct clades based on hemagglutinin amino acid sequences. According to the invention, multiple clades are used in influenza immunization. Thus there is a prime-boost immunization schedule where a subject receives a priming dose of a first clade of H5 influenza A virus and a boosting dose of a second clade of H5 influenza A virus. There is also an immunogenic composition comprising hemagglutinin antigens from more than one clade of H5 influenza A virus.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: June 6, 2017
    Assignee: Seqirus UK Limited
    Inventors: Audino Podda, Rino Rappuoli
  • Patent number: 9623114
    Abstract: The present provide vaccine and adjuvant formulation comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed on to a particle of metal salt and the resulting particle is essentially devoid of antigen.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: April 18, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Nathalie Garcon
  • Patent number: 9624185
    Abstract: The present disclosure provides a new method for preparing IDO inhibitor epacadostat. The whole reaction route is simple, easy to control and has high yield.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: April 18, 2017
    Inventor: Yong Xu
  • Patent number: 9561270
    Abstract: The present invention provides methods of reducing the virucidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: February 7, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Caroline Ann Kohler, Guosong Zhao, Ali Khazraeinazmpour, Bernd Colin Eichenmueller, Marc Allan Eichmeyer, Gregory Haiwick, Merrill Lynn Schaeffer
  • Patent number: 9535076
    Abstract: The present invention involves methods and compositions for treating, preventing, and diagnosing amyloid-associated diseases and conditions, as well as methods and compositions for making antigens that elicit antibodies which selectively or specifically bind amyloid prefibrillar oligomers or protofibrillar aggregates over monomers or fibrils of the same amyloid.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: January 3, 2017
    Assignee: The Regents of the University of California
    Inventors: Rakez Kayed, Charles G. Glabe
  • Patent number: 9522170
    Abstract: A method involves screening a candidate compound for activity in the treatment of a condition associated with formation of amyloid protein fibrils in a mammal, such as Alzheimer's disease. It is determined whether the trimer/monomer ratio of a chaperone protein is decreased in the presence of the candidate compound. The chaperone protein is or has a high identity to the Brichos domains of Bri2, Bri3 or proSP-C from human. Monomers of the chaperone proteins and/or compounds that promote formation of these monomers are useful for medical treatment of the condition.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 20, 2016
    Assignee: ALPHABETA AB
    Inventors: Jan Johansson, Jenny Presto
  • Patent number: 9522182
    Abstract: The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: December 20, 2016
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Vicky Fachinger, Knut Elbers, Marion Kixmoeller, Francois-Xavier Orveillon, Isabelle Freiin Von Richthofen, Axel Lischewski
  • Patent number: 9517260
    Abstract: The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: December 13, 2016
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Vicky Fachinger, Knut Elbers, Axel Lischewski, Marion Kixmoeller, Francois-Xavier Orveillon, Isabelle Freiin von Richthofen, Michael D. Piontkowski